References
- LiWQiuTLingYGuoLLiLYingJMolecular pathological epidemiology of colorectal cancer in Chinese patients with KRAS and BRAF mutationsOncotarget2015637396073961326530529
- Fernández-MedardeASantosERas in cancer and developmental diseasesGenes Cancer20112334435821779504
- DierschSWirthMSchneeweisCKras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cellsOncogene201635293880388626592448
- ZoccheDMRamirezCFontaoFMCostaLDRedalMAGlobal impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancerFront Genet2015611625870609
- SugayaAMoriwakiTTajimaDA retrospective analysis of cetuximab or panitumumab monotherapy for KRAS wild-type metastatic colorectal cancer in clinical practiceGan To Kagaku Ryoho2015422189193 Japanese [with English abstract]25743137
- WestwoodMvan AsseltTRamaekersBKRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysisHealth Technol Assess201418621132
- VignotSLefebvreCFramptonGMComparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profilesEur J Cancer201551779179925797355
- VakianiEJanakiramanMShenRComparative genomic analysis of primary versus metastatic colorectal carcinomasJ Clin Oncol2015302429562962
- LiWQiuTZhiWColorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stagesBMC Cancer20151534025929517
- OcvirkJBrodowiczTWrbaFCetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trialWorld J Gastroenterol201016253133314320593498
- HuangCWTsaiHLChenYTThe prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancerBMC Cancer20131359924330663
- RothADTejparSDelorenziMPrognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trialJ Clin Oncol201028346647420008640
- BazanVMigliavaccaMZannaISpecific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotypeAnn Oncol20021391438144612196370
- ZhangKXuJYanLLiuXXuFLiuYDetection of KRAS, NRAS and BRAF gene mutations in colorectal carcinomaZhonghua Bing Li Xue Za Zhi2015444254257 Chinese [with English abstract]25975908
- KodazHHacibekirogluIErdoganBAssociation between specific KRAS mutations and the clinicopathological characteristics of colorectal tumorsMol Clin Oncol20153117918425469291
- PaliogiannisPCossuATandaFPalmieriGPalombaGKRAS mutational concordance between primary and metastatic colorectal adenocarcinomaOncol Lett2014841422142625202344
- YamauchiMMorikawaTKuchibaAAssessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectumGut201261684785422427238
- BleekerWAHayesVMKarrenbeldAImpact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes’ C colon cancerAm J Gastroenterol200095102953295711051374
- ZulhabriORahmanJIsmailSIsaMRWan ZurinahWNPredominance of G to A codon 12 mutation K-ras gene in Dukes’ B colorectal cancerSingapore Med J2012531263122252179
- VelhoSOliveiraCSerucaRKRAS mutations and anti-epidermal growth factor receptor therapy in colorectal cancer with lymph node metastasesJ Clin Oncol20092715815919047277
- KleistBKempaMNovyMComparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancerInt J Clin Exp Pathol2014795927593925337237
- KadowakiSKakutaMTakahashiSPrognostic value of KRAS and BRAF mutations in curatively resected colorectal cancerWorld J Gastroenterol20152141275128325632202
- Siyar EkinciADemirciUCakmak OksuzogluBKRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinomaJ BUON201520112813525778307
- El-JawhariJJEl-SherbinyYMScottGBBlocking oncogenic RAS enhances tumour cell surface MHC class I expression but does not alter susceptibility to cytotoxic lymphocytesMol Immunol201458216016824365750
- NakanishiRHaradaJTuulMPrognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancerInt J Clin Oncol20131861042104823188063
- BournetBMuscariFBuscailCKRAS G12D mutation subtype is a prognostic factor for advanced pancreatic adenocarcinomaClin Transl Gastroenterol20167e15727010960